Clinical Trials · NCT02487823
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- Institut Paoli-Calmettes
- Enrollment
- 6
- Start date
- Oct 2014
- Locations
- 1 site, France
- Primary endpoint
- Determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in combination with daily bicalutamide and LH-RH agonists to men with non castrate metastatic prostate cancer